Clay Siegall is a business executive who lives and works in the greater Seattle region. He is one of the two co-founders of Seattle Genetics which is a biotech firm focused on creating drugs to treat cancer as well as other diseases where the mortality rates have not seen improvements in many years. He has a degree in zoology acquired at the University of Maryland and he is also a graduate of George Washington University where he earned a Ph.D. in genetics.
Since he co-founded Seattle Genetics in 1998 he has led his company to being one of the top companies in the targeted therapy sector. Seattle Genetics was the first company to receive FDA-approval for an antibody drug conjugate. This drug was approved to treat lymphoma and has now been approved for a number of other applications. In addition to this drug Clay Siegall says that his company has over 20 other drugs currently in the development pipeline. He has also built strategic partnerships with some of the biggest drug manufacturers in the world such as Bayer and Pfizer.
Clay Siegall says that he sees systemic chemotherapies and other older ways of treating cancer like it going into the historical dustbin. Targeted drug therapies are both much safer and more effective than those types of treatments. As time goes on newer drugs will replace them for most diseases and will be much better tolerated.
He says that growing up he was always interested in the world of medicine and wanted to one day come up with cures for people who would otherwise have been destined to die. He got interested specifically in cancer when he was studying for his bachelor’s degree and one of his family members developed this disease. It was during this time that he learned just how brutal the treatment regimen could be, at one point this treatment almost killing them. He then learned about other ways to treat cancer such as amputations and decided that there simply had to be a better way to go about it and that he would personally find them.